December 7, 2024
Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a responsibly-driven company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases. Our trials are designed to further evaluate the safety and efficacy of our acquired assets. These come to Seelos with well characterized efficacy and safety, thereby avoiding much of the lengthy and burdensome process of preclinical R&D.